Research!America unveils 2016 policy wish list

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

RESEARCH!AMERICA unveiled its policy wish list for 2016, urging Congress to take action on several research priorities.

“Congress should act this year to sustain robust funding for federal health agencies, advance medical innovation and mental health legislation, and permanently repeal the medical device tax,” they said in a statement.

The advocacy group said that additional funds for NIH and FDA will support innovative projects including precision medicine, Alzheimer’s research and efforts to combat antimicrobial resistance, however “the budget for the Agency for Healthcare Research and Quality was cut by eight percent in the spending bill, further limiting the agency’s ability to address costly errors and inefficiencies in health care delivery. Sustainable and predictable investments for AHRQ and other health agencies are critical to accelerating medical progress.”

The group also called attention to a bill being drafted by a Senate committee, called the Innovations for Healthier Americans Initiative, which is companion legislation for the 21st Century Cures bill, which passed in the House last year.

“Research!America urges Senate action early this year on legislation that responsibly modernizes regulatory pathways for new drugs and medical devices, and includes mandatory funding for the NIH and FDA. The goal must be to enact meaningful legislation this year.”

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login